

ASX Announcement

1 April 2025

TRP Appointment of Chief Financial Officer (CFO)

Tissue Repair Limited (ASX:TRP) ("**TRP**" or the "**Company**") announces the appointment of Mr. Dion Cohen to the role of Chief Financial Officer of the Company with effect from 31 March 2025.

Dion Cohen is a Chartered Accountant with over 15 years of experience in senior finance roles. He has worked across both listed and unlisted sectors with a focus on financial reporting, governance, capital management, and establishing streamlined finance functions to support growth.

TRP's CEO, Tony Charara said he was pleased to welcome Mr. Dion Cohen as a CFO of the Company.

The Company further advises that Mr Cohen will replace Mr Cameron Peter Jones as CFO, with effect from 31 March 2025. The Board wishes to thank Mr Jones for his services to the Company.

The Company had historically used an outsourced CFO functions and services through Bio101 Pty Limited and welcomes the additional focus from having an employed CFO to partner with the CEO and more directly with the TR-987 clinical teams executing the Phase III trial and the TR Pro+ product teams.

For further information in relation to this release please contact Sushma Kejriwal at s.kejriwal@acclime.com.

This announcement has been approved for release by TRP's board.

-ENDS-

About Tissue Repair

Tissue Repair Limited (ASX:TRP) is a Phase 3 advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987®, with a secondary focus on commercialising TR Pro+® a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures, as well as other acute wound products in its pipeline. The Company's longer-term strategy is to commercialise its propriety Glucoprime® API to treat a variety of wounds and skin conditions.